Processa Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Processa Pharmaceuticals, Inc. announced a change in the physical location for its upcoming 2025 Special Meeting of Stockholders.
NASDAQ
Processa Pharmaceuticals, Inc. calls a Special Meeting to vote on increasing authorized shares, a reverse stock split, and expanding its incentive plan.
NASDAQ
DEF 14A: Processa Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Processa Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held on June 30, 2025, to vote on director elections, warrant share issuance, auditor ratification, and executive compensation.
NASDAQ
Processa Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
DEFR14A: Processa Pharmaceuticals Discloses Executive Pay Versus Performance in Proxy Statement Supplement
Processa Pharmaceuticals provides a supplement to its definitive proxy statement, detailing the relationship between executive compensation and company performance metrics like total shareholder return and net income.
NASDAQ
Processa Pharmaceuticals has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Processa Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Omnibus Incentive Plan to increase the number of shares available for issuance by 500,000 at the Annual Meeting of Stockholders to be held June 28, 2024.